NasdaqGS - Nasdaq Real Time Price USD

Amphastar Pharmaceuticals, Inc. (AMPH)

41.11 +0.28 (+0.69%)
At close: April 26 at 4:00 PM EDT
41.00 -0.11 (-0.27%)
After hours: April 26 at 4:29 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
644,395.00
644,395.00
498,987.00
437,768.00
349,846.00
Cost of Revenue
293,274.00
293,274.00
250,127.00
238,029.00
206,506.00
Gross Profit
351,121.00
351,121.00
248,860.00
199,739.00
143,340.00
Operating Expense
154,134.00
154,134.00
141,363.00
129,852.00
132,386.00
Operating Income
196,987.00
196,987.00
107,497.00
69,887.00
10,954.00
Net Non Operating Interest Income Expense
-21,699.00
-21,699.00
-525.00
-284.00
268.00
Other Income Expense
-3,929.00
-3,929.00
9,068.00
14,536.00
-6,585.00
Pretax Income
171,359.00
171,359.00
116,040.00
84,139.00
4,637.00
Tax Provision
31,833.00
31,833.00
23,477.00
20,630.00
3,540.00
Earnings from Equity Interest Net of Tax
-1,981.00
-1,981.00
-1,177.00
-208.00
--
Net Income Common Stockholders
137,545.00
137,545.00
91,386.00
62,116.00
1,403.00
Diluted NI Available to Com Stockholders
137,545.00
137,545.00
91,386.00
62,116.00
1,403.00
Basic EPS
2.85
2.85
1.88
1.30
0.03
Diluted EPS
2.60
2.60
1.74
1.25
0.03
Basic Average Shares
48,265.00
48,265.00
48,551.00
47,777.00
47,038.00
Diluted Average Shares
53,001.00
53,001.00
52,427.00
49,784.00
49,124.00
Total Operating Income as Reported
196,987.00
196,987.00
107,497.00
69,887.00
10,954.00
Total Expenses
447,408.00
447,408.00
391,490.00
367,881.00
338,892.00
Net Income from Continuing & Discontinued Operation
137,545.00
137,545.00
91,386.00
62,116.00
1,403.00
Normalized Income
137,545.00
137,545.00
91,386.00
62,116.00
1,403.00
Interest Income
5,459.00
5,459.00
1,321.00
601.00
642.00
Interest Expense
27,158.00
27,158.00
1,846.00
885.00
374.00
Net Interest Income
-21,699.00
-21,699.00
-525.00
-284.00
268.00
EBIT
198,517.00
198,517.00
117,886.00
85,024.00
5,011.00
EBITDA
240,294.00
240,294.00
146,161.00
111,557.00
30,191.00
Reconciled Cost of Revenue
293,274.00
293,274.00
250,127.00
238,029.00
206,506.00
Reconciled Depreciation
41,777.00
41,777.00
28,275.00
26,533.00
25,180.00
Net Income from Continuing Operation Net Minority Interest
137,545.00
137,545.00
91,386.00
62,116.00
1,403.00
Normalized EBITDA
240,294.00
240,294.00
146,161.00
111,557.00
30,191.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
12/31/2020 - 6/25/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PCRX Pacira BioSciences, Inc.
26.33
+3.25%
 
ALKS Alkermes plc
24.68
+0.98%
 
PBH Prestige Consumer Healthcare Inc.
70.47
+0.47%
 
LNTH Lantheus Holdings, Inc.
65.56
+0.55%
 
IRWD Ironwood Pharmaceuticals, Inc.
7.82
-3.22%
 
COLL Collegium Pharmaceutical, Inc.
36.42
+1.62%
 
ITCI Intra-Cellular Therapies, Inc.
73.26
+1.57%
 
NBIX Neurocrine Biosciences, Inc.
135.99
-1.28%
 
CTLT Catalent, Inc.
55.92
+0.22%
 
ALVO Alvotech
14.15
+3.66%